Who
Paul Peter Tak
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Candel Therapeutics.
In numbers
- Trades disclosed
- 29
- Buys
- 3
- Sells
- 9
- Bought
- $230K
- Sold
- $7.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 29 Jul 2021
- Last trade
- 11 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 11 Sep 2026 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $621K59,379 at $10.46 | filing |
| 11 Sep 2026filed 11 Sep 2026 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $621K59,379 at $10.46 | filing |
| 10 Sep 2026filed 11 Sep 2026 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code M | $194K125,000 at $1.55 | filing |
| 10 Sep 2026filed 11 Sep 2026 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.5M220,866 at $11.50 | filing |
| 10 Sep 2026filed 11 Sep 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —125,000 at $0.00 | filing |
| 10 Sep 2026filed 11 Sep 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —125,000 at $0.00 | filing |
| 10 Sep 2026filed 11 Sep 2026 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code M | $194K125,000 at $1.55 | filing |
| 10 Sep 2026filed 11 Sep 2026 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.5M220,866 at $11.50 | filing |
| 26 Jan 2026filed 28 Jan 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —629,000 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —629,000 at $0.00 | filing |
| 25 Jun 2025filed 26 Jun 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code A | $200K42,826 at $4.67 | filing |
| 19 Mar 2025filed 20 Mar 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,600400 at $9.00 | filing |
| 18 Mar 2025filed 20 Mar 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $226K25,772 at $8.77 | filing |
| 12 Feb 2025filed 14 Feb 2025 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
| 15 Jan 2025filed 17 Jan 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $157K21,704 at $7.23 | filing |
| 8 Jan 2025filed 10 Jan 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $174K21,172 at $8.22 | filing |
| 29 Nov 2024filed 3 Dec 2024 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $223K48,847 at $4.56 | filing |
| 21 Nov 2024filed 21 Nov 2024 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,900 at $0.00 | filing |
| 21 Nov 2024filed 21 Nov 2024 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code M | $20K12,900 at $1.55 | filing |
| 17 Jul 2024filed 19 Jul 2024 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Sold | $146K22,528 at $6.47 | filing |
News
Candel Therapeutics to Present at November Investor ConferencesCADL · manilatimes.net · 27 Oct 2026Candel Therapeutics (NASDAQ:CADL) Shares Gap Up – Time to Buy?CADL · dailypolitical.com · 26 Oct 2026Candel Therapeutics Appoints Maria Ostrovsky as General CounselCADL · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name Paul Peter Tak; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.